Immunophotonics, Inc.
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | STING and inflammasome pathwaysPolysaccharide | Non-Small Cell Lung CancerColorectal Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2033 (1)
December 2033 (1)
N-dihydrogalactochitosanPhase 2/3Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases …
Est. primary completion 2033-12 · NCT07321847 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.